Porownywarka
Semaglutide Oral vs Semaglutide side-by-side
Zestaw do czterech peptydów według statusu dowodów, mechanizmów, dawkowania z badań, skutków ubocznych i referencji.
Porownywarka
Zestaw do czterech peptydów według statusu dowodów, mechanizmów, dawkowania z badań, skutków ubocznych i referencji.
Wybrane (2/4)
Udostępnij porównanie peptydów
| Wlasciwosc | Semaglutide Oral | Semaglutide |
|---|---|---|
| Kategoria | Redukcja masy | Redukcja masy |
| Znany tez jako | Semaglutide Oral, Rybelsus, Semaglutide | Ozempic, Wegovy, Rybelsus |
| Zatwierdzony przez FDA | Tak | Tak |
| Status kliniczny | FDA approved for Rybelsus in type 2 diabetes; cardiovascular-risk reduction (Oct 2025); and weight management with oral Wegovy 25 mg (Dec 2025), which the source calls the first oral GLP-1 for obesity.
| FDA-approved status recorded by the supplied source; it also reports several 2025-2026 indication and formulation updates.
|
| Czego oczekiwac | Oral use in type 2 diabetes and weight management. | Weight loss, appetite control, blood sugar management |
| Jak dziala | The supplied record identifies semaglutide as a GLP-1 receptor agonist and attributes appetite reduction, slower gastric emptying, and glucose-dependent insulin release to it. It describes co-formulation with SNAC (sodium N-(8-[2-hydroxybenzoyl]amino) caprylate), which is said to alter local gastric pH, limit digestive peptide breakdown, and facilitate passage through the gastric lining into blood. These mechanistic statements were not independently corroborated in the input. | According to the supplied description, semaglutide stimulates the GLP-1 receptor. Reported downstream effects include increased insulin secretion when glucose is elevated, decreased glucagon, slower gastric emptying, and hypothalamic appetite signaling. A fatty-acid modification is described as promoting albumin binding and as associated with an approximately 160 hour (about 160 hours) half-life, supporting weekly administration. |
| Typowe dawkowanie | Limited community data available · See research protocols | 1-2.4 mg weekly (after titration) · Once weekly |
| Dawkowanie z badań | 3mg daily (starting) · Long-term / chronic use · Oral tablet on empty stomach with <4oz water | 0.25mg weekly (starting) · Long-term / chronic use · Subcutaneous injection weekly, or oral (Rybelsus) |
| Typowy czas trwania | Long-term / chronic use | Long-term / chronic use |
| Podanie | Oral tablet on empty stomach with <4oz water | Subcutaneous injection weekly, or oral (Rybelsus) |
| Timing | Morning, immediately after waking, on an empty stomach The source associates empty-stomach administration with a 30 minute separation from food and additional fluid. | Morning, same day each week With or without food |
| Poziom dowodów | Zatwierdzone przez FDA | Zatwierdzone przez FDA |
| Mozliwe skutki uboczne |
+4 więcej
|
+10 więcej
|
| Podsumowanie researchu | The supplied record characterizes the evidence as published human-trial research. It reports that PIONEER included more than 9,500 people with type 2 diabetes, with A1C changes of roughly 0.6 to 1.4 percentage points and modest weight loss; sitagliptin and empagliflozin are named as comparators. For PIONEER PLUS, cited as published in The Lancet, the record compares 25 mg and 50 mg with 14 mg and reports greater A1C and weight reductions at the higher amounts. It reports an OASIS 1 comparison of 15.1 % weight loss at 50 mg versus 2.4 % with placebo. For OASIS 4 (NEJM, 2025), it states 13.6 % loss at a 64 week endpoint on 25 mg, described as comparable with injectable Wegovy. These reported results require review against the cited publications. | The source characterizes the clinical literature as extensive. It reports that the SUSTAIN program established blood-sugar control in type 2 diabetes and that SUSTAIN 6 reduced cardiovascular events. For STEP 1, published in the New England Journal of Medicine in 2021, the source describes nearly 2,000 adults without diabetes in a randomized trial: at a 68 week endpoint, semaglutide 2.4 mg had 14.9 % mean weight loss versus 2.4 % with placebo, and most participants lost at least 5 %. It characterizes this as large randomized, placebo-controlled research rather than pilot data. Gastrointestinal effects, including nausea, vomiting, and constipation, were reported as most prominent during escalation; the source also reports an oral weight-management version as approved. |
| Referencje | ||
| Pełny profil | Zobacz szczegóły | Zobacz szczegóły |
Zapisz to porównanie
Trzymaj ten zestaw researchowy pod reka na darmowym koncie PeptiGuide.
Zapisz porównanie - darmowe kontoTrackuj swoja ścieżkę peptydówa
Zamien research w prywatny log protokołu, gdy będziesz gotowy.
Trackuj ścieżkę peptydówaWyłącznie edukacyjnie. Te informacje są agregowane z publicznych badań i raportów społeczności. To nie jest poradą medyczną, a informacje o dawkowaniu są opisowe, nie rekomendacyjne. Zawsze konsultuj się z wykwalifikowanym specjalistą ochrony zdrowia.